6/7/2025

Janusmed sex and gender

Janusmed sex and gender – rifampicin sodium

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Rifampicin

Rifampicin

Class : A

Show all info

Print

Contact us

  1. Global tuberculosis report 2024. World Health Organization (WHO).

  2. Vårdprogram för led- och skelettinfektioner. Svensk infektionsläkarföreningen [www]. [updated 2023-07-11, cited 2025-04-22].

  3. WHO consolidated operational handbook on tuberculosis Module 4: treatment and care. World Health Organization (WHO).

  4. Vårdprogram tuberkulos. Svenska infektionsläkarföreningen [www]. [updated 2023-02-28, cited 2025-04-22].

  5. Medellín-Garibay SE, Milán-Segovia Rdel C, Magaña-Aquino M, Portales-Pérez DP, Romano-Moreno S. Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers. J Pharm Pharmacol. 2014;66(10):1421-8.

  6. Gafar F, Yunivita V, Fregonese F, Apriani L, Aarnoutse RE, Ruslami R et al. Pharmacokinetics of standard versus high-dose rifampin for tuberculosis preventive treatment: A sub-study of the 2R2 randomized controlled trial. Int J Antimicrob Agents. 2024;64(1):107197.

  7. McIlleron H, Rustomjee R, Vahedi M, Mthiyane T, Denti P, Connolly C et al. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother. 2012;56(6):3232-8.

  8. Bilal M, Ullah S, Jaehde U, Trueck C, Zaremba D, Wachall B et al. Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteers. Eur J Clin Pharmacol. 2024;80(9):1271-1283.

  9. Idris R, Dayani AZ, Groh AM, Mohr A, Koepsell J, Zielbauer AS et al. Sex-dependent variability of isoniazid and rifampicin serum levels in patients with tuberculosis. Infection. 2024;:.

  10. Lei Q, Wang H, Zhao Y, Dang L, Zhu C, Lv X et al. Determinants of serum concentration of first-line anti-tuberculosis drugs from China. Medicine (Baltimore). 2019;98(41):e17523.

  11. Requena-Méndez A, Davies G, Ardrey A, Jave O, López-Romero SL, Ward SA et al. Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. Antimicrob Agents Chemother. 2012;56(5):2357-63.

  12. Deshmukh S, Sane M, Gaikwad S, Sahasrabudhe T, Barthwal M, Lokhande R et al. Sex Differences in TB Clinical Presentation, Drug Exposure, and Treatment Outcomes in India. Chest. 2023;163(4):778-789.

  13. Chidambaram V, Tun NL, Majella MG, Ruelas Castillo J, Ayeh SK, Kumar A et al. Male Sex Is Associated With Worse Microbiological and Clinical Outcomes Following Tuberculosis Treatment: A Retrospective Cohort Study, a Systematic Review of the Literature, and Meta-analysis. Clin Infect Dis. 2021;73(9):1580-1588.

  14. Tonnelier M, Bouras A, Joseph C, Samad YE, Brunschweiler B, Schmit JL et al. Impact of rifampicin dose in bone and joint prosthetic device infections due to Staphylococcus spp: a retrospective single-center study in France. BMC Infect Dis. 2021;21(1):174.

  15. Teixeira LAA, Santos B, Correia MG, Valiquette C, Bastos ML, Menzies D et al. Long-Term Protective Effect of Tuberculosis Preventive Therapy in a Medium/High Tuberculosis Incidence Setting. Clin Infect Dis. 2024;78(5):1321-1327.

  16. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192-202.

  17. Campbell JR, Trajman A, Cook VJ, Johnston JC, Adjobimey M, Ruslami R et al. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis. 2020;20(3):318-329.

  18. Ruslami R, Fregonese F, Apriani L, Barss L, Bedingfield N, Chiang V et al. High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial. Lancet Respir Med. 2024;12(6):433-443.

  19. Rimactan (rifampicin). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-09-11, cited 2025-04-22]

  20. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]

  1. Global tuberculosis report 2024. World Health Organization (WHO).
  2. Vårdprogram för led- och skelettinfektioner. Svensk infektionsläkarföreningen [www]. [updated 2023-07-11, cited 2025-04-22].
  3. WHO consolidated operational handbook on tuberculosis Module 4: treatment and care. World Health Organization (WHO).
  4. Vårdprogram tuberkulos. Svenska infektionsläkarföreningen [www]. [updated 2023-02-28, cited 2025-04-22].
  5. Medellín-Garibay SE, Milán-Segovia Rdel C, Magaña-Aquino M, Portales-Pérez DP, Romano-Moreno S. Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers. J Pharm Pharmacol. 2014;66(10):1421-8.
  6. Gafar F, Yunivita V, Fregonese F, Apriani L, Aarnoutse RE, Ruslami R et al. Pharmacokinetics of standard versus high-dose rifampin for tuberculosis preventive treatment: A sub-study of the 2R2 randomized controlled trial. Int J Antimicrob Agents. 2024;64(1):107197.
  7. McIlleron H, Rustomjee R, Vahedi M, Mthiyane T, Denti P, Connolly C et al. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother. 2012;56(6):3232-8.
  8. Bilal M, Ullah S, Jaehde U, Trueck C, Zaremba D, Wachall B et al. Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteers. Eur J Clin Pharmacol. 2024;80(9):1271-1283.
  9. Idris R, Dayani AZ, Groh AM, Mohr A, Koepsell J, Zielbauer AS et al. Sex-dependent variability of isoniazid and rifampicin serum levels in patients with tuberculosis. Infection. 2024;:.
  10. Lei Q, Wang H, Zhao Y, Dang L, Zhu C, Lv X et al. Determinants of serum concentration of first-line anti-tuberculosis drugs from China. Medicine (Baltimore). 2019;98(41):e17523.
  11. Requena-Méndez A, Davies G, Ardrey A, Jave O, López-Romero SL, Ward SA et al. Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. Antimicrob Agents Chemother. 2012;56(5):2357-63.
  12. Deshmukh S, Sane M, Gaikwad S, Sahasrabudhe T, Barthwal M, Lokhande R et al. Sex Differences in TB Clinical Presentation, Drug Exposure, and Treatment Outcomes in India. Chest. 2023;163(4):778-789.
  13. Chidambaram V, Tun NL, Majella MG, Ruelas Castillo J, Ayeh SK, Kumar A et al. Male Sex Is Associated With Worse Microbiological and Clinical Outcomes Following Tuberculosis Treatment: A Retrospective Cohort Study, a Systematic Review of the Literature, and Meta-analysis. Clin Infect Dis. 2021;73(9):1580-1588.
  14. Tonnelier M, Bouras A, Joseph C, Samad YE, Brunschweiler B, Schmit JL et al. Impact of rifampicin dose in bone and joint prosthetic device infections due to Staphylococcus spp: a retrospective single-center study in France. BMC Infect Dis. 2021;21(1):174.
  15. Teixeira LAA, Santos B, Correia MG, Valiquette C, Bastos ML, Menzies D et al. Long-Term Protective Effect of Tuberculosis Preventive Therapy in a Medium/High Tuberculosis Incidence Setting. Clin Infect Dis. 2024;78(5):1321-1327.
  16. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192-202.
  17. Campbell JR, Trajman A, Cook VJ, Johnston JC, Adjobimey M, Ruslami R et al. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis. 2020;20(3):318-329.
  18. Ruslami R, Fregonese F, Apriani L, Barss L, Bedingfield N, Chiang V et al. High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial. Lancet Respir Med. 2024;12(6):433-443.
  19. Rimactan (rifampicin). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-09-11, cited 2025-04-22]
  20. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]